Skip to main content

Publications and presentations

  • 2015-2016 publications

    Tsai ML, Lillemoe TJ, Finkelstein MJ, Money JE, Susnik B, Grimm E, Kang SHL, Swenson KK. Utility of Oncotype Dx® Risk Assessment in Patients with Invasive Lobular Carcinoma. Clinical Breast Cancer. 2015 Aug 19 pii: S1526-8209 [Epub ahead of print].

    Wagner LI, Zhao F, Williams ME, Gascoyne RD, Krauss JC, Advani RH, Go RS, Habermann TM, Leach JW, O’Connor B, Schuster SJ, Cella D, Horning SJ, Kahl BS. Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECPG trial E4402 (RESORT), J Clin Oncol. 2015 Mar 1;33(7):740-8.

    Vergote I, Schilder RJ, Pippitt CH Jr, Wong S, Gordon AN, Scudder S, Kridelka F, Dirix L, Leach JW, et al. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. Gynecol Oncol. 2014 Oct; 135(1): 25-33. [Epub ahead of print 2014 Jul 11].

    Dostal AM, Samavat H, Torkelson C, Bedell S, Wang R, Swenson KK, Wu AH, Ursin G, Le C, Yuan JM, Kurzer MS. The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: Results of the Minnesota Green Tea Trial. Food Chem Toxicol. 2015 Sep;83:26-35. [Epub ahead of print].

    Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncology 2015;33(25), 2780-2788. [Epub ahead of print].

    Kim C, Economou S, Amatruda TT, Martin JC, Dudek AZ. Prognostic significance of microscopic tumor burden in sentinel lymph node in patients with cutaneous melanoma. Anticancer Research. 2015 Jan;35(1):301-309.

    Asztalos S, Pham TN, Gann PH, Hayes MK, Deaton R, Wiley EL, Emmadi R, Kajdacsy-Balla A, Banerji N, McDonald W, Khan SA, Tonetti DA. High incidence of triple negative breast cancers following pregnancy and an associated gene expression signature. Springerplus. 2015 Nov 19; 4:710.

    Schultz KA, Baldinger SR, Harris A, Sencer S, Messinger Y. Ovarian tumors related to intronic mutations in DICER1: A report from the International Ovarian and Testicular Stromal Tumor Registry. Familial Cancer, 2015 Aug 20. [Epub ahead of print].

    Susnik B, Day D, Abeln E, Bowman T, Krueger J, Swenson KK, Tsai ML, Bretzke ML, Lillemoe T. Surgical outcome of lobular neoplasia diagnosed in core biopsy: Prospective study of 316 cases. Clinical Breast Cancer. 2016 Jun 14. Pii: S1526-8209(16)30145-8. [Epub ahead of print].

    Thumbigere-Math V, Michalowicz B, deJong E, Griffin T, Basi D, Hughes P, Tsai M, Swenson K, Rockwell L, Gopalakrishnan R. Salivary proteomics in bisphosphonate-related osteonecrosis of the jaw. Oral Dis. 2015;21(1):46-56.

    Thumbigere-Math V, Michalowicz BS, Hughes PJ, Basi DL, Tsai ML, Swenson KK, Rockwell L, Gopalakrishnan R. Serum markers of bone turnover and angiogenesis in patients with bisphosphonate-related osteonecrosis of the jaw after discontinuation of long-term intravenous bisphosphonate therapy. J Oral Maxillofac Surg. 2016 Apr; 74(4):738-746. Doi:10.1016/j.joms.2015.09.028.  Epub 2015 Oct 3.

    Goy A, Forero A, Wagner-Johnston N, Ehmann C, Tsai M, Hatake K, Ananthakrishnan R, Volkert A, Vandendries E, Ogura M. A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy or radioimmunotherapy. Br J Haematol. 2016 Apr 22 doi: 10.1111/bjh.14094. [Epub ahead of print].

    Reddy SK, Parker RJ, Leach JW, Hill MJ, Burgart LJ. Tumor histopathology predicts outcomes after resection of colorectal cancer liver metastases treated with and without pre-operative chemotherapy. J Surg Oncol. 2016 Mar;113(4): 456-462. Epub 2016 Jan 12.

    Kaufman HL, Amatruda T, Reid T, Gonzalez R, Glaspy J, Whitman E, Harrington K, Nemunaitis J, Zloza A, Wolf M, Senzer NN. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. J Immonother Cancer. 2016 Mar 15;4:12. eCollection 2016.

    Poster and podium presentations

    Picozzi VJ, Seng JE, Leach J, Larson T, et al. Phase II study of nab-Paclitaxel/Gemcitabine alternating with FOLFIRI and 1st line therapy in patients with metastatic pancreatic cancer. Poster presentation at the 2015 ASCO, Chicago, IL.

    Kelly K , Leach J, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study. Poster presentation at the 2015 ASCO, Chicago, IL.

    Gulley J, Leach J. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. Poster presentation at the 2015 ASCO, Chicago, IL.

    Kaufman H, Amatruda T, Nemunaitis JJ, Chesney JA, Delman KA, Spitler LE, et al. Tumor size and clinical outcomes in melanoma patients treated with talimogene laherparepvec (T-VEC). Poster presentation at 2015 ASCO Annual Meeting, June 1, 2015, Chicago, IL.

    Nookala A, Henn A, Shamsi N, Finkelstein M, Smith C, Reddy S, Min M, Ricci P. Outcome of hepatic resection for hepatocellular carcinoma in patients without cirrhosis. Poster presentation at the 2015 International Liver Cancer Association Annual Conference,  Sept 4-6, 2015, Paris, France.

    Tsai ML, Finkelstein MJ, Lillemoe TJ, Susnik B, Grimm E, Kang, S-H, Kelly C, Swenson KK. Evaluation of the pathologic predictors of treatment response to neoadjuvant chemotherapy for invasive lobular breast cancer. Poster presentation at the AACR: Advances in Breast Cancer Research Meeting, Bellevue, WA, Oct 17-20, 2015.

    Leach J. Early clinical trials evaluating cell-based, checkpoint inhibitors and novel immunotherapeutics. Podium presentation at the AACR Annual Meeting 2016 in New Orleans, Louisiana, April 19, 2016.

    Quinlan-Woodward J, Gode A, Kolste A, Reinstein A, Dusek J, Trebesch D, Migliori M, Johnson J, Sendelback S. A pilot randomized controlled trial to assess the impact of acupuncture on post-mastectomy pain, nausea, anxiety and ability to cope. Poster presentation at the 40th Annual ONS Congress, Orlando, FL, April 2015.

    Bendel A, Skrypek M, Hansen M, Wein A, Kebriaei M, Baldinger S, Pacheco MC, Helseth P, Bhambhani V, Crabb B. Case report of metastatic atypical teratoid rhabdoid tumor (ATRT) secondary to an inherited germline mutation in the SMARCA4 gene: literature review and recommendations for tumor surveillance of asymptomatic carriers. Poster presentation at the International Symposium on Pediatric Neuro-Oncology, LiverPool, England, June 12-15, 2016.

    Overman M, Kopetz S, McDermott R, Leach J, Lonardi S, Lenz H-J, Morse M, Desai J, Hill A, Axelson M, Moss RA, Lin C-S, Goldberg M, Andre T. Nivolumab (N) ± ipilimumab (I) in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. Podium presentation at the ASCO Annual Meeting, June 2016.

    Hassan R, Thomas A, Patel M, Nemunaitis J, Bennouna J, Powderly J, Taylor M, Dowlati A, Chen F, Leach J, Vaishampayan U, Verschraegen C, Delord JP, Grote HJ, von Heydebreck A, Cuilerot JM, Gulley JL. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase 1b trial: safety, clinical activity, and PD-L1 expression. Podium presentation at the ASCO Annual Meeting, June 2016. 

    Tsai M, Untch S, Treece T, Lo Shelly, Soliman H, PROMIS Investigators Group. The 70-gene signature provides risk stratification and treatment guidance for patients classified as intermediate by the 21-gene assay. Poster presentation at the ASCO Annual Meeting, June 2016.

    Kelly K, Patel M, Infante JR, Iannotti N, Leach J, Wang D, Chandler J, Arkenau HT, Taylor M, Gordon M, Wong DJ, Safran H, Kaufman H, Keiholz U, Bajars M, von Heydebreck A, Speit I, Cuilerot JM, Gulley JL.  Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced malignancy: safety data from 1300 patients enrolled in the phase Ib JAVELIN solid tumor trial. Poster presentation at the ASCO Annual Meeting, June 2016.

    Kne A, Zierhut H, Baldinger S, Swenson K, Mink P, Tsai M. Why is cancer genetic counseling underutilized by women identified as at risk for hereditary breast cancer? Patient perceptions of barriers following a referral letter. Poster presentation at the NSGC Annual Education Conference, Seattle, WA, September 28-Oct 1, 2016.

    Schneider L, Braatz C, Lillemoe T, Finkelstein M, Krueger J, Swenson K, Tsai M, Susnik B. Pathology and imaging findings in patients with contralateral cancer diagnosed on preoperative staging MRI imaging. Poster presentation at the European Society of Breast Imaging Annual Scientific Meeting, Sept 2016, Paris, France.

    Lillemoe TJ, Susnik B, Grimm E, Kang S, Swenson KK, Krueger J, Finkelstein MJ, Tsai ML. The association of higher tumor HER2 load with treatment response to neoadjuvant therapy in HER2 positive breast cancer patients. Poster presentation at the San Antonio Breast Conference, December 2016.

    Susnik B, Lillemoe TJ, Tsai ML, Finkelstein MJ, Schneider L, Braatz C, Krueger J, Swenson K, Rueth N. Predictive value of breast MRI in detecting mammographically occult contralateral breast cancer: Can we target women more likely to have contralateral breast cancer based on primary tumor clinicopathologic factors? Poster presentation at the San Antonio Breast Conference, December 2016.